Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients with High-grade Cervical Intraepithelial Lesions Treated with Imiquimod

NCT06356012 is registered in ClinicalTrials.gov with Barretos Cancer Hospital as lead sponsor.

NCT NCT06356012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06356012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients with High-grade Cervical Intraepithelial Lesions Treated with Imiquimod
Lead sponsor
Barretos Cancer Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
April 2, 2024
Completion date
December 31, 2028
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarkers, hsil, high-grade squamous intraepithelial lesions, vaginal microbiome